Gu S N, Qiang W T, Lu J, Feng Z Y, Du J
Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):951-955. doi: 10.3760/cma.j.cn121090-20240426-00165.
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments. This article reports the case of an IgD type relapsed and refractory MM patient with poor efficacy of BCMA×CD3 bispecific antibody. The patient achieved deep remission after receiving BCMA-targeted CAR-T cell therapy after initial seven lines of treatment. Literature review was also conducted to improve the clinical physicians' understanding of BCMA target therapy for relapsed and refractory MM patients.
多发性骨髓瘤（MM）是一种目前无法治愈的恶性浆细胞疾病。近年来不断有几种新药问世。与传统治疗方法相比，靶向B细胞成熟抗原（BCMA）的新药极大地改善了MM的疗效和预后。本文报告了1例IgD型复发难治性MM患者，其接受BCMA×CD3双特异性抗体治疗效果不佳。该患者在最初接受7线治疗后，接受靶向BCMA的嵌合抗原受体T细胞（CAR-T）治疗后实现了深度缓解。还进行了文献综述，以提高临床医生对复发难治性MM患者BCMA靶向治疗的认识。
